跳至主要内容
临床试验/NCT02222376
NCT02222376已完成3 期

Effect of Treatment of Diabetic Foot Ulcers With Topic 8% 1-phenyl-5-methyl-2-[1h]-Pyridone (Pirfenidone) Combined With Modified Disulfur Diallyl Oxide (Odd-m) in Gel.

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2013年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
36
试验地点
1
主要终点
Ulcer size

研究概览

简要总结

Pirfenidone is a synthetic molecule, which acts as a potent modulator of the effect of various cytokines (TNF-α, transforming growth factor-β, platelet derived growth factor and vascular endothelial growth factor, among others) that possesses anti-inflammatory and anti-fibrinolytic properties.

The aim of this study is to compare the effect of topic treatment with pirfenidone compared to conventional treatment in chronic diabetic foot ulcers.

The hypothesis is that treatment with topic pirfenidone in chronic diabetic foot ulcers (Wagner 1 to 2) reduces the ulcer size and shortens the healing time compared to conventional treatment. This is a randomized, controlled and crossover study. Patients will be randomly assigned to conventional treatment or topic pirfenidone for eight weeks. At the end of this period they will change groups. Each week ulcers will be for size, depth, length and evidence of infection. The ulcers will have proper debridement in the conventional treatment group and debridement plus topical pirfenidone application in the pirfenidone group. Subjects will be instructed to do daily ulcer cleansing and for those in the topical pirfenidone group, in addition to cleansing they will be instructed to apply the gel twice a day.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women
  • Type 1 or 2 diabetes
  • Age ≥ 18 years
  • Wagner 1 or 2 diabetic foot ulcer
  • Diabetic ulcer for more than 8 weeks duration
  • Willing to participate in the study with signed informed consent

排除标准

  • Ankle/brachial index < 0.4 (critic ischemia)
  • Use topical or systemic antibiotics
  • Inability to attend to the weekly evaluations
  • Inability to do daily ulcer cleansing
  • Autoimmune diseases
  • Active pharmacologic topical or systemic ulcer treatment
  • Treatment with immunosuppressors such as steroids, radiotherapy, chemotherapy
  • Pregnancy or lactation

研究组 & 干预措施

Conventional treatment

Active Comparator

Weekly ulcer debridement and daily cleansing

干预措施: Debridement (Procedure)

Pirfenidone

Experimental

Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application

干预措施: Pirfenidone (Drug)

Pirfenidone

Experimental

Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application

干预措施: Debridement (Procedure)

结局指标

主要结局

Ulcer size

时间窗: 16 weeks

次要结局

未报告次要终点

研究者

发起方
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验